NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
Want to see NAMS full AI Analyst Report?
Top Page
NewAmsterdam Pharma Company
(NASDAQ:NAMS)
Select Model
Select Model
Rating:55Neutral
Price Target:
$36.00
▲(3.81% Upside)
Action:ReiteratedDate:03/03/26
The score is anchored by solid financial stability from a low-debt balance sheet, but held back by persistent losses and ongoing cash burn. Technicals are mixed with near-term weakness, while valuation is penalized by negative earnings and no dividend support. Positive recent corporate updates provide some offset via clinical/regulatory progress and funding runway.
Positive Factors
Balance Sheet Strength
A near-zero debt profile with sizeable equity and assets provides durable financial flexibility. This reduces refinancing risk, supports continued trial funding and commercialization investments, and enables strategic optionality (partnerships/M&A) while development milestones progress.
Negative Factors
Sustained Cash Burn
Consistent multi-year negative operating and free cash flow is a structural risk: it depletes reserves without commercialization, necessitates future financing or partnerships, and increases dilution or covenant risk if clinical/regulatory timelines slip or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A near-zero debt profile with sizeable equity and assets provides durable financial flexibility. This reduces refinancing risk, supports continued trial funding and commercialization investments, and enables strategic optionality (partnerships/M&A) while development milestones progress.
Read all positive factors
NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.91B
Dividend YieldN/A
Average Volume (3M)825.03K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees68
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.63
Shares Outstanding114,975,426
10 Day Avg. Volume797,778
30 Day Avg. Volume825,032
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue155.43
Enterprise Value/Gross Profit155.83
Enterprise Value/Ebitda-14.43
Forecast
1Y Price Target
$49.78Price Target Upside43.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$27.77M
NewAmsterdam Pharma Company Business Overview & Revenue Model
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets t...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, NewAmsterdam Pharma’s ability to generate recurring commercial revenue is limited until it obtains regulatory approvals and launches products. Publicly available sources do not provide sufficient, con...
NewAmsterdam Pharma Company Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
86
Very Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.50M | 45.56M | 14.09M | 102.69M | 0.00 |
| Gross Profit | 22.44M | 45.56M | 14.09M | 102.69M | 0.00 |
| EBITDA | -242.32M | -241.49M | -176.86M | -22.34M | -41.37M |
| Net Income | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
Balance Sheet | |||||
| Total Assets | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M |
| Cash, Cash Equivalents and Short-Term Investments | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M |
| Total Debt | 202.00K | 448.00K | 60.00K | 126.00K | 186.51K |
| Total Liabilities | 85.85M | 107.12M | 58.70M | 48.43M | 11.36M |
| Stockholders Equity | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M |
Cash Flow | |||||
| Free Cash Flow | -148.03M | -159.24M | -141.24M | 10.44M | -29.54M |
| Operating Cash Flow | -147.78M | -158.56M | -141.22M | 10.66M | -29.51M |
| Investing Cash Flow | -174.92M | -62.85M | -24.00K | -221.00K | -24.00K |
| Financing Cash Flow | 29.52M | 659.51M | 8.91M | 391.90M | 84.70M |
NewAmsterdam Pharma Company Technical Analysis
Positive
34.68
Price Trends
32.75
Positive
33.83
Positive
31.21
Positive
Market Momentum
0.78
Negative
56.92
Neutral
36.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Positive. The current price of 34.68 is above the 20-day moving average (MA) of 32.64, above the 50-day MA of 32.75, and above the 200-day MA of 31.21, indicating a bullish trend. The MACD of 0.78 indicates Negative momentum. The RSI at 56.92 is Neutral, neither overbought nor oversold. The STOCH value of 36.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAMS.
NewAmsterdam Pharma Company Risk Analysis
NewAmsterdam Pharma Company disclosed 91 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NewAmsterdam Pharma Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.71B | 117.86 | 5.90% | ― | ― | 44.84% | |
69 Neutral | $3.51B | 51.87 | 11.48% | ― | 55.68% | ― | |
62 Neutral | $5.58B | -10.43 | -65.80% | ― | ― | -27.70% | |
58 Neutral | $5.62B | -10.27 | -55.81% | ― | ― | -38.30% | |
55 Neutral | $3.91B | -19.69 | -27.47% | ― | ― | ― | |
52 Neutral | $4.10B | -6.36 | -48.04% | ― | ― | -126.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NAMS
NewAmsterdam Pharma Company
34.68
18.42
113.28%
VKTX
Viking Therapeutics
35.20
11.48
48.40%
XENE
Xenon
59.70
25.00
72.05%
SLNO
Soleno Therapeutics
52.78
-16.15
-23.43%
KNSA
Kiniksa Pharmaceuticals
44.90
24.85
123.94%
IMVT
Immunovant
29.30
14.84
102.63%
NewAmsterdam Pharma Company Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
Positive
Mar 2, 2026
On March 2, 2026, NewAmsterdam Pharma posted an updated corporate investor presentation detailing recent clinical, commercial, and financial progress around its lead candidate obicetrapib. The company highlighted Phase 2 and Phase 3 data indicatin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.